🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Dear Mira and Ilya - congratulations on your coup at OpenAI. Since both of you have together never raised a penny as entrepreneurs, let me explain what happens. Oh, and you *will* need to raise since your venture’s unit economics don’t make sense. Remember, you pay $0.30 every

Incredibly proud and grateful to be partnered Zavain Dar Adam Goulburn Nan Li ! Congrats on year 1 of many 🚀

Envedians August Allen and Pelle Simpson teamed up with collaborators at Bruker on this article in Drug Target Review describing how we use advanced mass spectrometry to power our search for new medicines from nature. Read on to learn more: drugtargetreview.com/article/141908…

Adding another very important award to our tally. We couldn't be more proud of the culture and community we have built @envedabio! If you are looking for your next mission, please check out our open roles (many more coming soon) here: envedabio.com/careers

Tomorrow, Oct 16 at 1:50 PM ET, Enveda CEO @ViswaColluru will be on the panel *"An Integrative AI Mindset"* discussing how AI, metabolomics, & automation will help us translate nature into new medicines!  Register: events.endpts.com/aiday24#regist…📷📷 #AI #DrugDiscovery

Today the emotions are many but words are few. I’ll save the latter for a longer post soon. Let’s go Enveda ! 🚀

Our friends at NYSE 🏛 celebrated our Series C on their trading floor. Thank you, Eric J. Dimise, PhD , Johanna Grossman, PhD and other NYSE colleagues!

2024 was an incredible year for Enveda. Thank you to everyone who made it possible! 🎉 2025 is gearing up to be even more incredible. Stay tuned! 🚀

What if you had a platform that can simultaneously discover new targets *and* leads at scale? Just how many molecules exist in the entire plant kingdom? Read on to find out in this inaugural edition of In-Veda from Enveda

Asthma is close to my heart. It can be debilitating and scary — especially if your inhaler isn’t nearby. We’re incredibly excited about the potential for ENV-294 to offer a non-steroidal oral option for long-term use!

Despite the high prevalence of #asthma and >1.6M asthma-related ER visits every year, no new oral asthma drugs have been approved in over two decades. That's why we are excited to advance ENV-294. ENV-294 could transform asthma treatment, offering a first-in-class therapy that

This is a special one for us at Enveda: rooted in what matters most in drug discovery, the promise of your drugs. Let’s go!

In case you missed the largest gathering in tech last month, our CEO and Founder Viswa Colluru discussed the future of AI and healthcare. "AI matches, recognizes and generates patterns and it will help move medical science forward..." Watch here: youtu.be/em5xz5Oyg_w?fe…

Sanofi is a global leader in the treatment of atopic dermatitis and other inflammatory diseases. Their investment supports the promise of using AI to learn from life’s chemistry — not just in accelerating new medicines but in expanding our fundamental understanding of the

More than we thought... Our latest research, just published in GigaScience, reveals something incredible: the chemical diversity of plants is far greater than previously thought, potentially reaching more than 𝘁𝗲𝗻𝘀 𝗼𝗳 𝗺𝗶𝗹𝗹𝗶𝗼𝗻𝘀 𝗼𝗳 𝘂𝗻𝗶𝗾𝘂𝗲 𝗰𝗼𝗺𝗽𝗼𝘂𝗻𝗱𝘀.

🚀 What if the cure for tomorrow’s toughest disease is already hiding in nature — and we could find it four times faster than anyone else? That’s the reality our CTO August Allen unveils in Microsoft's #TechInnovators Spotlight. Key takeaways: 🌿 Nature’s pharmacy holds

What will healthcare look like in the next 10 years? Precision biotech sits at the intersection of AI, chemistry, and unmet medical needs that are evolving with society—exactly where Enveda’s platform delivers. This week, the spotlight shifts to Tirana, Albania as FII Institute

More than a clinical milestone – this marks real momentum for our lead asset. Our first-in-class oral therapeutic, ENV-294, cleared a major Phase I milestone with favorable safety results and it's showing potential to transform care for #atopicdermatitis patients. Read more:

Filming at the BBC felt surreal. An average student with no gift for biology… Standing at the Barbican with my favorite author, Nick Lane. Telling the story of a company we built from belief. Enveda’s mission is simple: Turn life’s chemistry into hope — for the people we love.